Alla studier
RekryteringFAS3INTERVENTIONELL

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

This research study, called YOSEMITE, is looking into a new medicine called zodasiran. It's for teenagers and adults, aged 12 and over, who have a rare and severe inherited condition called homozygous familial hypercholesterolemia (HoFH). HoFH causes extremely high cholesterol levels from birth, which can lead to serious heart problems at a young age. The study aims to find out if zodasiran injections are safe and effective at lowering these high cholesterol levels. Some participants will receive zodasiran, while others will receive a dummy medicine (placebo) first, before everyone eventually gets the active drug. Your participation could help improve treatments for HoFH in the future.

Överblick

Status
Rekrytering
Fas
FAS3
Sponsor
Arrowhead Pharmaceuticals
Inskrivningsmål
60
Starta
17 Jun 2025
Beräknad slutförande
20 Aug 2027

Vad handlar denna studie om?

Imagine your body struggling to clear out bad cholesterol, leading to dangerously high levels from a very young age. This is what happens to people with Homozygous Familial Hypercholesterolemia (HoFH), a rare and serious inherited condition. These extremely high cholesterol levels can cause serious health problems, including heart disease, much earlier in life than usual.

This study, named YOSEMITE, is testing a new medicine called zodasiran. Researchers want to see if zodasiran can safely and effectively lower the very high cholesterol levels in people aged 12 and over with HoFH. By taking part, you could help doctors understand more about how to manage this condition and potentially improve future treatments.

The study is 'double-blind', meaning neither you nor your doctor will know if you are receiving zodasiran or a dummy medicine (placebo) at first. This helps ensure the results are accurate. After this initial period, everyone will have the chance to receive the actual zodasiran medicine in a longer, open-label part of the study.

Viktiga punkter

  • This study is testing a new medicine for severe inherited high cholesterol (HoFH).
  • It's for people aged 12 and above.
  • Participants will receive either zodasiran or a dummy medicine first.
  • Everyone can eventually receive the active medicine.
  • The goal is to see if zodasiran can safely lower cholesterol levels.
  • Your participation could help advance HoFH treatment.

Vem kan vara berättigad?

To join this study, you would need to be at least 12 years old and weigh at least 35 kg (about 5 stone 7 pounds). If you can become pregnant, you shouldn't be pregnant or breastfeeding, and should not plan to become pregnant during the study.

You would need to have a confirmed diagnosis of HoFH, either through a genetic test or based on certain cholesterol levels and other signs like fatty deposits on your skin or tendons from a young age. Your 'bad' cholesterol (LDL-C) levels would also need to be above a certain amount, even if you're already taking cholesterol-lowering medicines.

There are also some health conditions or medicines that would prevent you from joining. For example, if you've recently used certain other trial medicines or have severe kidney problems, you might not be able to take part. The study also requires you to be stable on your current cholesterol-lowering medicines.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du 12 år eller äldre?
  2. Do you have a diagnosis of HoFH?
  3. Are you currently on cholesterol-lowering medicines?
  4. If female, are you not pregnant or breastfeeding, and not planning to become pregnant during the study?
  5. Are your cholesterol levels still high despite existing treatment?
  6. Do you meet the weight requirement of at least 35 kg?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to join, you'll first be randomly assigned to receive either the study medicine, zodasiran, or a dummy medicine (placebo) through injections under your skin. Neither you nor your study doctor will know which you are receiving at this stage. This initial 'double-blind' period will last for several months.

Throughout the study, you'll have regular visits to the clinic for health checks, blood tests, and to make sure the treatment is working and you're not experiencing any problems. After the initial period, you'll have the option to continue in a longer part of the study where everyone will receive the active zodasiran medicine. We don't have the exact number of visits or the total length of the study available right now, but these details would be explained fully by the study team.

Potentiella risker och fördelar

Taking part in a study like this can have potential benefits, such as receiving a new treatment that might help lower your cholesterol levels. You'll also receive close medical attention and contribute valuable information that could help others with HoFH in the future. However, there are also potential risks, including side effects from the study medicine or discomfort from injections and blood tests. Remember, you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (43)

  • Forskningsplats 7
    Verifierat postnummer
    Park Ridge, USA· Rekrytering
  • Research Site 2
    Verifierat postnummer
    New York, USA· Rekrytering
  • Forskningsplats 1
    Verifierat postnummer
    Cincinnati, USA· Rekrytering
  • Forskningsplats 14
    Verifierat postnummer
    Pittsburgh, USA· Rekrytering
  • Forskningsplats 13
    Verifierat postnummer
    Camperdown, Australien· Rekrytering
  • Forskningsplats 9
    Endast stad
    Saint Leonards, Australia· Rekrytering
  • Research Site 21
    Verifierat postnummer
    Heidelberg, Australien· Rekrytering
  • Research Site 3
    Verifierat postnummer
    Nedlands, Australien· Rekrytering
  • Research Site 40
    Verifierat postnummer
    Innsbruck, Österrike· Rekrytering
  • Research Site 39
    Verifierat postnummer
    Linz, Österrike· Rekrytering
  • Research Site 42
    Verifierat postnummer
    Wien, Österrike· Rekrytering
  • Research Site 37
    Verifierat postnummer
    Wien, Österrike· Rekrytering

Vanliga frågor

What is HoFH?

HoFH (Homozygous Familial Hypercholesterolemia) is a very rare inherited condition that causes extremely high cholesterol levels from birth, leading to a high risk of heart disease at a young age.

What is zodasiran?

Zodasiran is an investigational medicine being tested in this study to see if it can help lower very high cholesterol levels in people with HoFH.

Vad är en 'placebo'?

A placebo is a dummy treatment that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers accurately see if the real medicine is effective.

Kommer jag att veta om jag får den riktiga medicinen?

For the first part of the study, neither you nor your doctor will know if you're getting zodasiran or the placebo. Later, everyone will have the option to receive the active zodasiran.

Hur ges medicinen?

The study medicine, zodasiran, is given as an injection under the skin.

Hur du får reda på mer

Medical Monitor

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Phase 3 Study of Zodasiran in Adolescent and Adult Subject…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.